Heterozygous pathogenic variants in POMC are not responsible for monogenic obesity: Implication for MC4R agonist use

Genet Med. 2023 Jul;25(7):100857. doi: 10.1016/j.gim.2023.100857. Epub 2023 Apr 21.

Abstract

Purpose: Recessive deficiency of proopiomelanocortin (POMC) causes childhood-onset severe obesity. Cases can now benefit from the melanocortin 4 receptor agonist setmelanotide. Furthermore, a phase 3 clinical trial is evaluating setmelanotide in heterozygotes for POMC. We performed a large-scale genetic analysis to assess the effect of heterozygous, pathogenic POMC variants on obesity.

Methods: A genetic analysis was performed in a family including 2 cousins with childhood-onset obesity. We analyzed the obesity status of heterozygotes for pathogenic POMC variants in the Human Gene Mutation Database. The association between heterozygous pathogenic POMC variants and obesity risk was assessed using 190,000 exome samples from UK Biobank.

Results: The 2 cousins carried a compound heterozygous pathogenic variant in POMC. Six siblings were heterozygotes; only 1 of them had obesity. In Human Gene Mutation Database, we identified 60 heterozygotes for pathogenic POMC variants, of whom 14 had obesity. In UK Biobank, heterozygous pathogenic POMC variants were not associated with obesity risk, but they modestly increased body mass index levels.

Conclusion: Heterozygous pathogenic POMC variants do not contribute to monogenic obesity, but they slightly increase body mass index. Setmelanotide use in patients with obesity, which would only be based on the presence of a heterozygous POMC variant, can be questioned.

Keywords: Heterozygous; Hypocortisolism; Obesity; POMC; Variant.

MeSH terms

  • Anti-Obesity Agents / therapeutic use
  • Body Mass Index
  • Child
  • Heterozygote
  • Humans
  • Mutation
  • Obesity / genetics
  • Pediatric Obesity* / genetics
  • Pro-Opiomelanocortin* / genetics
  • Receptor, Melanocortin, Type 4 / agonists
  • Receptor, Melanocortin, Type 4 / genetics

Substances

  • Pro-Opiomelanocortin
  • Receptor, Melanocortin, Type 4
  • setmelanotide
  • Anti-Obesity Agents